From IPEX syndrome to <i>FOXP3</i> mutation: a lesson on immune dysregulationRosa Bacchetta, Maria‐Grazia Roncarolo, Federica Barzaghi|Annals of the New York Academy of Sciences|2016Cited by 341
Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective studyFederica Barzaghi, Rakesh K. Goyal, Carsten Speckmann et al.|Journal of Allergy and Clinical Immunology|2017Cited by 313
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded accessFrancesca Fumagalli, Alessandro Aiuti, Valeria Calbi et al.|The Lancet|2022Cited by 286
A combined immunodeficiency with severe infections, inflammation, and allergy caused by ARPC1B deficiencyStefano Volpi, Rae S. M. Yeung, Maria Pia Cicalese et al.|Journal of Allergy and Clinical Immunology|2019Cited by 119
CRISPR-based gene editing enables <i>FOXP3</i> gene repair in IPEX patient cellsMarianne Goodwin, Rosa Bacchetta, Uma Lakshmanan et al.|Science Advances|2020Cited by 113